2-(5-chloro-2-fluorophenyl)-4-(3-ethyl-4-pyridylamino)pteridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 2-(5-chloro-2-fluorophenyl)-4-(3-ethyl-4-pyridylamino)pteridine
• 英文别名: 2-(5-chloro-2-fluorophenyl)-N-(3-ethylpyridin-4-yl)pteridin-4-amine
• 化学式: C₁₉H₁₄ClFN₆
• 分子量: 380.812
• InChiKey: ATXRZVQEHKHQAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-氯-2-氟苯甲酰氯 在 吡啶 、 sodium hydroxide 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氨 作用下， 以 乙醇 为溶剂， 生成 2-(5-chloro-2-fluorophenyl)-4-(3-ethyl-4-pyridylamino)pteridine
  参考文献：
  名称：

  Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

  摘要：

  Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-2-fluoro-phenyl)pteridin-4-ylamino]-N-[3-(2-oxopyrrolidin-1-yl)propyl]nicotinamide 36 with a replicon EC50 of 64 nM, associated with a selective kinase inhibitory profile for human JNK kinases 2 and 3 as well as VEGFR-1, 2, and 3 kinases. Moreover, 36 showed an advantageous PK profile in mice. Experiments performed using different replicon constructs suggest that this series of kinase inhibitors might mediate their effect through the HCV non-structural protein 5A (NS5A). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.046

文献信息

• QUINAZOLINE DERIVATIVES AS MEDICAMENTS
  申请人：DUGAR Sundeep

  公开号：US20070293500A1

  公开（公告）日：2007-12-20

  Quinazoline derivatives and their pharmaceutically acceptable salts are inhibitors of TGFβ activity and are used to treat conditions characterized by enhanced TGFβ activity.

  喹唑啉衍生物及其药学上可接受的盐是TGFβ活性的抑制剂，用于治疗TGFβ活性增强的疾病。
• Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：US20140094468A1

  公开（公告）日：2014-04-03

  The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

  本发明涉及使用蚀刻酸类作为HCV复制抑制剂，以及它们在旨在治疗或对抗HCV感染的药物组合物中的使用。此外，本发明涉及化合物本身及其作为药物的使用。本发明还涉及制备这种化合物的过程，包括它们的制药组合物，以及与其他抗HCV药物的复合物。
• Pteridines useful as HCV inhibitors and methods for the preparation thereof
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：US09290502B2

  公开（公告）日：2016-03-22

  The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

  本发明涉及使用黄素类物质作为HCV复制抑制剂，以及它们在旨在治疗或对抗HCV感染的药物组合物中的使用。此外，本发明涉及化合物本身及其作为药物的使用。本发明还涉及制备这种化合物的过程，包括它们的制药组合物以及与其他抗HCV剂的复合物。
• PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：EP1881834A1

  公开（公告）日：2008-01-30
• US7232824B2
  申请人：——

  公开号：US7232824B2

  公开（公告）日：2007-06-19